Brain-derived neurotrophic factor in hematological malignancies: From detrimental to potentially beneficial.

David Azoulay, Netanel A Horowitz

Blood reviews 2022 Jan

filter terms:

Emerging studies have highlighted brain-derived neurotrophic factor (BDNF), a neuronal growth factor abundant in the peripheral blood, and its tyrosine kinase receptor TRKB, as onco-genes and proteins that support the survival of malignant hematological cells. In contrast, other researchers reported on a favorable association between BDNF blood levels and prognosis, chemotherapy response and neurological side effects in patients with hematological malignancies. Here, we review the accumulated data regarding the expression of BDNF and its receptors in normal hematopoietic and lymphatic cells and tissue. In addition, in-vitro experiments, animal models and human sample studies that investigated the role of BDNF and its receptors in hematological malignancies are discussed. Finally, directions for future research aimed at revealing the mechanisms underlying the protective effect of BDNF in patients with these diseases are suggested. Copyright © 2021 Elsevier Ltd. All rights reserved.

Citation

David Azoulay, Netanel A Horowitz. Brain-derived neurotrophic factor in hematological malignancies: From detrimental to potentially beneficial. Blood reviews. 2022 Jan;51:100871